Cagrilintide (Long-Acting Amylin Analogue) 10 mg × 10 vials — Research-Grade Long-Acting Amylin Analogue

Document ID: HKPW-cagrilintide-10-mg-amylin-analog-researc-v1.0 | Reviewed by: HKPEPTIDE WORLDWIDE Research Team | Last Updated: 2026-08-08

Product Identity & Specifications

Parameter	Specification
Product Name	Cagrilintide (Long-Acting Amylin Analogue)
Dosage	10 mg × 10 vials
CAS Number	1415456-99-3
Molecular Formula	C₁₈₂H₂₉₃N₄₇O₅₅
Molecular Weight	~4,100.7 Da
Sequence	Long-acting amylin analogue with strategic amino acid substitutions
Purity	≥99% HPLC
Appearance	White to off-white lyophilized powder
Solubility	Soluble in sterile water or bacteriostatic water
Storage	2–8°C, desiccated, protected from light
Classification	Long-Acting Amylin Analogue

Research Background

Cagrilintide is a long-acting amylin analogue engineered for metabolic research. Amylin is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic β-cells that regulates postprandial glucose through three complementary mechanisms: delayed gastric emptying, suppressed glucagon secretion, and central appetite modulation via the area postrema. Cagrilintide’s design incorporates strategic amino acid substitutions that confer amylin receptor (AMY-R) selectivity and an extended pharmacokinetic profile suitable for chronic metabolic research protocols. As the amylin pathway is mechanistically independent from the GLP-1 incretin pathway, Cagrilintide is frequently studied in combination with GLP-1 receptor agonists (Semaglutide, Tirzepatide) to evaluate dual-pathway metabolic intervention strategies.

The 10 mg × 10 vials configuration is manufactured under strict quality control protocols. Each batch undergoes HPLC purity verification, ESI-MS identity confirmation, and amino acid analysis. A batch-specific Certificate of Analysis (COA) is included with every order. Bulk and OEM configurations available for qualifying wholesale accounts.

Molecular Mechanisms

Amylin Receptor (AMY-R) Agonism

Selective activation of AMY-R (CTR/RAMP1 complex) in the area postrema → central appetite suppression and delayed gastric emptying. AMY-R signaling is independent of GLP-1R and GIPR — targeting a distinct node in metabolic regulation.

Postprandial Glucagon Suppression

Amylin-mediated suppression of pancreatic α-cell glucagon secretion → reduced hepatic glucose output after meals. This complements GLP-1’s insulinotropic effect, providing dual control over postprandial glucose.

Gastric Emptying Delay

AMY-R activation on vagal afferents → reduced gastric motility → slower nutrient delivery to the small intestine → attenuated postprandial glucose excursions. Synergistic with GLP-1’s gastric emptying effects.

Cagrilintide + Semaglutide Synergy

Cagrilintide (amylin pathway) + Semaglutide (GLP-1 pathway) → dual-pathway metabolic intervention targeting independent satiety and glucose regulatory mechanisms. Pre-formulated Cag/Sema fixed-dose kits available.

Research Applications

Amylin Receptor Pharmacology
Dual-Pathway Metabolic Research (AMY-R + GLP-1R)
Appetite & Satiety Signaling
Postprandial Glucose Regulation
Gastric Emptying & GI Motility

Comparative Analysis

Compared to GLP-1 agonists (Semaglutide, Tirzepatide): Cagrilintide targets the amylin pathway — a mechanistically distinct metabolic signaling system. While GLP-1 agonists primarily enhance insulin secretion and slow gastric emptying through incretin receptors, Cagrilintide suppresses glucagon and modulates central appetite through AMY-R. The combination (Cag/Sema) provides dual-pathway coverage targeting both incretin and amylin systems simultaneously.

Quality Control & Analytical Specifications

Parameter	Method	Specification
Purity	HPLC at 214 nm, C18 column	≥99.0% peak area
Identity (MW)	ESI-MS	~4,100.7 Da
Appearance	Visual inspection	White to off-white powder
Peptide Content	Amino acid analysis	≥80% net peptide
Residual Moisture	Karl Fischer titration	≤3%
Endotoxin	LAL assay	≤0.5 EU/mg

Available Configurations

Configuration	Content	Best For
Standard Kit	10 mg × 10 vials × 10 vials	Evaluation; protocol validation
Bulk Kit	Custom × 10 vials	Chronic studies; repeat orders
OEM/Private Label	Custom	Branded product development

Frequently Asked Questions

Q: How does Cagrilintide differ from GLP-1 agonists?

Cagrilintide targets the amylin receptor (AMY-R) in the area postrema — a distinct pathway from GLP-1R. Amylin suppresses glucagon and modulates appetite; GLP-1 enhances insulin secretion. Both slow gastric emptying, but through different receptor systems. The Cag/Sema combination targets both pathways.

Q: What is the Cagrilintide + Semaglutide synergy?

Cagrilintide activates amylin receptors → glucagon suppression + central appetite modulation. Semaglutide activates GLP-1 receptors → insulin secretion + gastric emptying delay. Together: dual-pathway metabolic intervention with complementary mechanisms. Pre-formulated Cag/Sema fixed-dose blend kits available.

Q: What makes Cagrilintide long-acting?

Strategic amino acid substitutions confer enhanced metabolic stability and reduced renal clearance compared to native amylin. This extended pharmacokinetic profile enables once-daily administration in chronic research protocols — comparable to once-weekly GLP-1 agonists in terms of protocol convenience.

Tiered Wholesale Pricing

Volume	Discount	For
1 kit	List price	Evaluation; competitive analysis
5+ kits	10% off	Initial portfolio expansion
20+ kits	20% off	Mid-size distributors
50+ kits	30% off	Regional distributors

Contact our team for 100+ kit custom pricing. Mixed-molecule orders qualify for combined volume tiers.

Resource	Description
Glp 1 Metabolic Peptides Hub	Complete research overview & methodology hub
Cagrilintide 10 Mg Amylin Analog Researc	Related research peptide product
Cagrilintide 5 Mg Amylin Research Peptid	Related research peptide product
Glp 1 Peptides Metabolic Research	Latest research insights & methodology

View Complete Research Guide »

Compliance Statement

FOR LABORATORY RESEARCH USE ONLY. Not for human or veterinary diagnostic, therapeutic, or prophylactic use. Not a dietary supplement, pharmaceutical ingredient, or approved drug. Researchers must comply with all applicable institutional, local, and national regulations.

Cagrilintide 10 mg